Robert Nettleship Brems, MD in Phoenix, AZ - Medicare Ophthalmology

Robert Nettleship Brems, MD is a medicare enrolled "Ophthalmology" physician in Phoenix, Arizona. He went to University Of Utah School Of Medicine and graduated in 1987 and has 37 years of diverse experience with area of expertise as Ophthalmology. He is a member of the group practice Associated Ophthalmologists Ltd and his current practice location is 300 E Osborn Rd, 100, Phoenix, Arizona. You can reach out to his office (for appointments etc.) via phone at (602) 200-0770.

Robert Nettleship Brems is licensed to practice in Arizona (license number 20722) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1205926623.

Contact Information

	Robert Nettleship Brems, MD
	300 E Osborn Rd, 100, Phoenix, AZ 85012
	(602) 200-0770
	(602) 294-0363

Physician's Profile

Full Name	Robert Nettleship Brems
Gender	Male
Speciality	Ophthalmology
Experience	37 Years
Location	300 E Osborn Rd, Phoenix, Arizona
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Robert Nettleship Brems attended and graduated from University Of Utah School Of Medicine in 1987

NPI Data:

NPI Number: 1205926623
Provider Enumeration Date: 10/14/2006
Last Update Date: 03/16/2011

Medicare PECOS Information:

PECOS PAC ID: 6406898063
Enrollment ID: I20110315001079

Medical Identifiers

Medical identifiers for Robert Nettleship Brems such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1205926623	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	20722 (Arizona)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Associated Ophthalmologists Ltd	8325024805	20

News Archive

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that AMRI's high potency research laboratories and GMP-manufacturing facilities in Rensselaer, New York have met the criteria established under the SafeBridge program for "Potent Compound Safety Certification" and have been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients ("APIs").

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Robert Nettleship Brems allows following entities to bill medicare on his behalf.

Entity Name	Associated Ophthalmologists Ltd
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1487704581 PECOS PAC ID: 8325024805 Enrollment ID: O20040625000445

News Archive

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Robert Nettleship Brems is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Robert Nettleship Brems, MD 300 E Osborn Rd, 100, Phoenix, AZ 85012 Ph: (602) 200-0770	Robert Nettleship Brems, MD 300 E Osborn Rd, 100, Phoenix, AZ 85012 Ph: (602) 200-0770

News Archive

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Ophthalmology Doctors in Phoenix, AZ

Dr. Christopher M. Fecarotta, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9305 W Thomas Rd Ste 460, Phoenix, AZ 85037 Phone: 602-933-3937 Fax: 602-933-2409
Aileen F Villareal, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4400 N 32nd St, Ste 280, Phoenix, AZ 85018 Phone: 602-266-6888 Fax: 602-266-6895
Mr. Sharam Danesh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4045 E Union Hills Dr Ste 115, Phoenix, AZ 85050 Phone: 602-368-3448 Fax: 602-357-3323
Madhavi Kurli, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 19820 N 7th St, Suite 120, Phoenix, AZ 85024 Phone: 480-397-9560 Fax: 480-397-9561
Rima Bharat Patel, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1750 E Glendale Ave, Phoenix, AZ 85020 Phone: 602-242-4928 Fax: 602-249-4813
Daniel Patrick Dansdill, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 4800 N 22nd St Ste 120, Phoenix, AZ 85016 Phone: 602-955-1000 Fax: 602-508-4830
James L Plotnik, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1920 E Cambridge Ave Ste 203, Phoenix, AZ 85006 Phone: 602-933-3937 Fax: 602-933-2409

Robert Nettleship Brems, MD - Medicare Ophthalmology in Phoenix, AZ

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Novartis presents 6-month results from its EVEREST study for PCV

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Medicare Reassignments

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Novartis presents 6-month results from its EVEREST study for PCV

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

AMRI's Rensselaer labs and manufacturing facilities receive SafeBridge Potent Compound Safety Certification

Novartis presents 6-month results from its EVEREST study for PCV

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Ophthalmology Doctors in Phoenix, AZ